Chronic myelogenous leukemia, version 1.2014: Featured updates to the NCCN guidelines

Susan O'Brien, Jerald P. Radich, Camille N. Abboud, Mojtaba Akhtari, Jessica K. Altman, Ellin Berman, Daniel J. DeAngelo, Michael Deininger, Steven Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Patricia Kropf, Joseph O. Moore, Arnel Pallera, Javier Pinilla-Ibarz, Vishnu V.B. Reddy, Neil P. Shah, B. Douglas Smith, David S. SnyderMeir Wetzler, Kristina Gregory, Hema Sundar

Research output: Contribution to journalReview article

46 Citations (Scopus)

Abstract

The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method for monitoring molecular response to tyrosine kinase inhibitor (TKI) therapy. A BCR-ABL1 transcript level of 10% or less (IS) is now included as the response milestone at 3 and 6 months. Change of therapy to an alternate TKI is recommended for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with imatinib. Continuing the same dose of TKI or switching to an alternate TKI are options for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with dasatinib or nilotinib. The guidelines recommend 6-month evaluation with QPCR (IS) for patients with BCR-ABL1 transcript levels greater than 10% at 3 months. Monitoring with QPCR (IS) every 3 months is recommended for all patients, including those who meet response milestones at 3, 6, 12, and 18 months (BCR-ABL1 transcript level ≤10% [IS] at 3 and 6 months, complete cytogenetic response at 12 and 18 months).

Original languageEnglish (US)
Pages (from-to)1327-1340
Number of pages14
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume11
Issue number11
DOIs
StatePublished - Nov 1 2013

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Guidelines
Reverse Transcription
Polymerase Chain Reaction
Therapeutics
Practice Guidelines
Cytogenetics

ASJC Scopus subject areas

  • Oncology

Cite this

O'Brien, S., Radich, J. P., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., ... Sundar, H. (2013). Chronic myelogenous leukemia, version 1.2014: Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 11(11), 1327-1340. https://doi.org/10.6004/jnccn.2013.0157

Chronic myelogenous leukemia, version 1.2014 : Featured updates to the NCCN guidelines. / O'Brien, Susan; Radich, Jerald P.; Abboud, Camille N.; Akhtari, Mojtaba; Altman, Jessica K.; Berman, Ellin; DeAngelo, Daniel J.; Deininger, Michael; Devine, Steven; Fathi, Amir T.; Gotlib, Jason; Jagasia, Madan; Kropf, Patricia; Moore, Joseph O.; Pallera, Arnel; Pinilla-Ibarz, Javier; Reddy, Vishnu V.B.; Shah, Neil P.; Douglas Smith, B.; Snyder, David S.; Wetzler, Meir; Gregory, Kristina; Sundar, Hema.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 11, No. 11, 01.11.2013, p. 1327-1340.

Research output: Contribution to journalReview article

O'Brien, S, Radich, JP, Abboud, CN, Akhtari, M, Altman, JK, Berman, E, DeAngelo, DJ, Deininger, M, Devine, S, Fathi, AT, Gotlib, J, Jagasia, M, Kropf, P, Moore, JO, Pallera, A, Pinilla-Ibarz, J, Reddy, VVB, Shah, NP, Douglas Smith, B, Snyder, DS, Wetzler, M, Gregory, K & Sundar, H 2013, 'Chronic myelogenous leukemia, version 1.2014: Featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 11, no. 11, pp. 1327-1340. https://doi.org/10.6004/jnccn.2013.0157
O'Brien, Susan ; Radich, Jerald P. ; Abboud, Camille N. ; Akhtari, Mojtaba ; Altman, Jessica K. ; Berman, Ellin ; DeAngelo, Daniel J. ; Deininger, Michael ; Devine, Steven ; Fathi, Amir T. ; Gotlib, Jason ; Jagasia, Madan ; Kropf, Patricia ; Moore, Joseph O. ; Pallera, Arnel ; Pinilla-Ibarz, Javier ; Reddy, Vishnu V.B. ; Shah, Neil P. ; Douglas Smith, B. ; Snyder, David S. ; Wetzler, Meir ; Gregory, Kristina ; Sundar, Hema. / Chronic myelogenous leukemia, version 1.2014 : Featured updates to the NCCN guidelines. In: JNCCN Journal of the National Comprehensive Cancer Network. 2013 ; Vol. 11, No. 11. pp. 1327-1340.
@article{dec7fb2fc8ae44848110ed08932e5778,
title = "Chronic myelogenous leukemia, version 1.2014: Featured updates to the NCCN guidelines",
abstract = "The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method for monitoring molecular response to tyrosine kinase inhibitor (TKI) therapy. A BCR-ABL1 transcript level of 10{\%} or less (IS) is now included as the response milestone at 3 and 6 months. Change of therapy to an alternate TKI is recommended for patients with BCR-ABL1 transcript levels greater than 10{\%} (IS) at 3 months after primary treatment with imatinib. Continuing the same dose of TKI or switching to an alternate TKI are options for patients with BCR-ABL1 transcript levels greater than 10{\%} (IS) at 3 months after primary treatment with dasatinib or nilotinib. The guidelines recommend 6-month evaluation with QPCR (IS) for patients with BCR-ABL1 transcript levels greater than 10{\%} at 3 months. Monitoring with QPCR (IS) every 3 months is recommended for all patients, including those who meet response milestones at 3, 6, 12, and 18 months (BCR-ABL1 transcript level ≤10{\%} [IS] at 3 and 6 months, complete cytogenetic response at 12 and 18 months).",
author = "Susan O'Brien and Radich, {Jerald P.} and Abboud, {Camille N.} and Mojtaba Akhtari and Altman, {Jessica K.} and Ellin Berman and DeAngelo, {Daniel J.} and Michael Deininger and Steven Devine and Fathi, {Amir T.} and Jason Gotlib and Madan Jagasia and Patricia Kropf and Moore, {Joseph O.} and Arnel Pallera and Javier Pinilla-Ibarz and Reddy, {Vishnu V.B.} and Shah, {Neil P.} and {Douglas Smith}, B. and Snyder, {David S.} and Meir Wetzler and Kristina Gregory and Hema Sundar",
year = "2013",
month = "11",
day = "1",
doi = "10.6004/jnccn.2013.0157",
language = "English (US)",
volume = "11",
pages = "1327--1340",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "11",

}

TY - JOUR

T1 - Chronic myelogenous leukemia, version 1.2014

T2 - Featured updates to the NCCN guidelines

AU - O'Brien, Susan

AU - Radich, Jerald P.

AU - Abboud, Camille N.

AU - Akhtari, Mojtaba

AU - Altman, Jessica K.

AU - Berman, Ellin

AU - DeAngelo, Daniel J.

AU - Deininger, Michael

AU - Devine, Steven

AU - Fathi, Amir T.

AU - Gotlib, Jason

AU - Jagasia, Madan

AU - Kropf, Patricia

AU - Moore, Joseph O.

AU - Pallera, Arnel

AU - Pinilla-Ibarz, Javier

AU - Reddy, Vishnu V.B.

AU - Shah, Neil P.

AU - Douglas Smith, B.

AU - Snyder, David S.

AU - Wetzler, Meir

AU - Gregory, Kristina

AU - Sundar, Hema

PY - 2013/11/1

Y1 - 2013/11/1

N2 - The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method for monitoring molecular response to tyrosine kinase inhibitor (TKI) therapy. A BCR-ABL1 transcript level of 10% or less (IS) is now included as the response milestone at 3 and 6 months. Change of therapy to an alternate TKI is recommended for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with imatinib. Continuing the same dose of TKI or switching to an alternate TKI are options for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with dasatinib or nilotinib. The guidelines recommend 6-month evaluation with QPCR (IS) for patients with BCR-ABL1 transcript levels greater than 10% at 3 months. Monitoring with QPCR (IS) every 3 months is recommended for all patients, including those who meet response milestones at 3, 6, 12, and 18 months (BCR-ABL1 transcript level ≤10% [IS] at 3 and 6 months, complete cytogenetic response at 12 and 18 months).

AB - The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method for monitoring molecular response to tyrosine kinase inhibitor (TKI) therapy. A BCR-ABL1 transcript level of 10% or less (IS) is now included as the response milestone at 3 and 6 months. Change of therapy to an alternate TKI is recommended for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with imatinib. Continuing the same dose of TKI or switching to an alternate TKI are options for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with dasatinib or nilotinib. The guidelines recommend 6-month evaluation with QPCR (IS) for patients with BCR-ABL1 transcript levels greater than 10% at 3 months. Monitoring with QPCR (IS) every 3 months is recommended for all patients, including those who meet response milestones at 3, 6, 12, and 18 months (BCR-ABL1 transcript level ≤10% [IS] at 3 and 6 months, complete cytogenetic response at 12 and 18 months).

UR - http://www.scopus.com/inward/record.url?scp=84891954191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891954191&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2013.0157

DO - 10.6004/jnccn.2013.0157

M3 - Review article

C2 - 24225967

AN - SCOPUS:84891954191

VL - 11

SP - 1327

EP - 1340

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 11

ER -